Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
Accutane, acne, acneiform, ACORN, adalimumab, adapalene, aimed, alopecia, Amnesteem, API, apportioned, areata, artificially, Avage, Avita, BBA, Benzaclin, Benzamycin, Biden, BMS, BPCA, Brexit, buy, calcineurin, carcinoma, category, cervical, CGI, chemotherapy, Circle, clindamycin, closure, cobolimab, colorectal, comorbidity, complaint, CPRA, deficient, delete, DGCL, dibutyl, Differin, dinitrochlorobenzene, diphencyprone, dismissed, dMMREC, draft, dry, Duac, duty, EGFRi, elongation, endometrial, enrichment, epidemic, epidemiology, epidermal, Erythema, erythromycin, ester, explained, fallopian, Festival, fiduciary, fluid, foot, group, hard, harder, Harmonisation, HARP, hereinafter, HHS, Humira, ill, illegitimate, imaging, implanted, impression, imsidolimab, incapacitated, infused, infusion, inherited, inhibitor, inquired, INSPIRE, instilled, instructed, inversa, isotretinoin, ix, journey, kinase, lab, Lanham, learning, liarozole, lowest, LP, MAA, magnitude, MEKi, mismatch, nationwide, neutrophilia, nondeductible, nonessential, Northern, NPS, occlusion, oncological, opine, opt, outpatient, ovarian, pandemic, Pandion, papulopustular, PARP, PdMMRT, peritoneal, physical, plaintiff, poly, polymerase, poverty, PPPASI, prejudice, pro, proscribed, qualitative, quantitative, RADIANCE, rash, rata, rectal, recurrent, registry, relaxing, remote, remotely, rentable, repair, rixolitinib, sanitation, sarcoma, sarecycline, scarring, sequelae, Seysara, shareholder, Shield, shutdown, solid, Southern, squaric, stoppage, strain, stronger, suppurativa, surgery, suspect, symptomatic, tailored, tazarotene, Tazorac, telework, tenant, thickened, thing, thoughtful, threat, thrive, tie, tofacitinib, top, tretinoin, Trex, trillion, tube, tumor, unchanged, unclear, unconstitutional, unexpired, unjust, unspecified, uphold, upregulated, urged, vast, vi, vigorously, vii, viii, Virtual, vitiligo, voluntarily, waste, Wateridge, workforce, workplace, Wuhan, Zejula
Removed:
AAAAI, AAD, acceleration, activation, acute, AE, AEs, aged, allergic, AMG, Amgen, analyzed, anrukinzumab, anti, array, asthma, AstraZeneca, atopy, AUD, BEAT, benralizumab, biotech, Bulletin, cancelable, capitalization, cellular, central, CHIP, chosen, Cinqair, collaborator, Composite, content, converted, creditable, cut, deductibility, Dermira, detachable, detection, differentiate, differentiated, distinctive, downstream, dysfunction, efficient, endothelial, eosinophilic, erosion, exacerbating, exceeded, excluding, exempt, Expiratory, fasenra, FceRI, formula, GDP, GILTI, graph, handful, Harmonization, helper, ICS, IgE, implicated, imposing, inadequately, inapplicable, incidence, ineligible, inhibited, Innate, intangible, internalized, intervened, intervention, invested, kickback, Kyoto, LABA, leader, lebrikizumab, LIBOR, Likewise, linked, MAD, mast, mediator, mepolizumab, MHRA, mononuclear, mucosal, mutated, mutation, neutropenia, noncurrent, notably, Nucala, Obama, obstructive, omalizumab, orchestrate, passed, PBMC, peanut, persistent, Pfizer, pharmacokinetic, plaque, post, preceded, presently, prioritized, prodromal, proved, provisional, pulmonary, purification, Reauthorization, reclassification, reclassified, refund, Regeneron, reinvestment, reliably, renew, repealing, repeatedly, requesting, rescue, reslizumab, resultant, revalued, Roche, SAB, SAD, secured, sera, SGR, soluble, stable, stimulation, structural, subset, supplemental, Sustainable, Taxation, terminal, territorial, Teva, tezepelumab, throughput, titer, tralokinumab, Unaudited, understood, unfold, University, upstream, version, warrant, Xolair
Filing tables
Filing exhibits
Related press release
ANAB similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of DirectorsÂ
AnaptysBio, Inc.:
We consent to the incorporation by reference in the registration statement (Nos. 333-215741, 333-223446, 333-229927, and 333-236805) on Form S-8 of AnaptysBio, Inc. of our report dated February 25, 2021, with respect to the consolidated balance sheets of AnaptysBio, Inc. as of December 31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2020, and the related notes (collectively, the consolidated financial statements), which report appears in the December 31, 2020 annual report on Form 10-K of AnaptysBio, Inc.
/s/ KPMG LLP
San Diego, California
February 25, 2021
February 25, 2021